# A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors

Source: https://onco.cc/trials/nct06777316/  
OnCo record `nct06777316` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of CGT4859 in biliary tract cancer, run by Cogent Biosciences, Inc., active and no longer recruiting.

## Summary

A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06777316 by Cogent Biosciences, Inc., with 110 participants enrolled, started 2025-01-22 and due to reach its primary completion in 2027-03. Interventions recorded: CGT4859.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06777316
- Phase: 1/2
- Setting: A Phase 1/2 Study of a Selective FGFR2/3 Inhibitor, CGT4859, in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors Harboring FGFR2 and/or FGFR3 Genetic Alterations
- Sponsor: Cogent Biosciences, Inc.
- Enrolled: 110

## Sources

- ClinicalTrials.gov NCT06777316: https://clinicaltrials.gov/study/NCT06777316

## Connected records

- cancers: [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/)
- drugs: [CGT4859](https://onco.cc/drugs/cgt4859/)
- companies: [Cogent Biosciences](https://onco.cc/companies/cogent-biosciences/)

---
JSON: https://onco.cc/api/v1/entities/nct06777316.json